These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 28992104)
1. A simplified and sensitive method to identify Alzheimer's disease biomarker candidates using patient-derived induced pluripotent stem cells (iPSCs). Shirotani K; Matsuo K; Ohtsuki S; Masuda T; Asai M; Kutoku Y; Ohsawa Y; Sunada Y; Kondo T; Inoue H; Iwata N J Biochem; 2017 Dec; 162(6):391-394. PubMed ID: 28992104 [TBL] [Abstract][Full Text] [Related]
2. Multiple reaction monitoring assay based on conventional liquid chromatography and electrospray ionization for simultaneous monitoring of multiple cerebrospinal fluid biomarker candidates for Alzheimer's disease. Choi YS; Lee KH Arch Pharm Res; 2016 Mar; 39(3):390-7. PubMed ID: 26404792 [TBL] [Abstract][Full Text] [Related]
3. Human Pluripotent Stem Cells as In Vitro Models of Neurodegenerative Diseases. Machairaki V Adv Exp Med Biol; 2020; 1195():93-94. PubMed ID: 32468463 [TBL] [Abstract][Full Text] [Related]
4. Generation of an induced pluripotent stem cell cohort suitable to investigate sporadic Alzheimer's Disease. Schöndorf DC; Elschami M; Schieck M; Ercan-Herbst E; Weber C; Riesinger Y; Kalman S; Steinemann D; Ehrnhoefer DE Stem Cell Res; 2019 Jan; 34():101351. PubMed ID: 30611016 [TBL] [Abstract][Full Text] [Related]
5. Induced pluripotent stem cell-derived neuronal cells from a sporadic Alzheimer's disease donor as a model for investigating AD-associated gene regulatory networks. Hossini AM; Megges M; Prigione A; Lichtner B; Toliat MR; Wruck W; Schröter F; Nuernberg P; Kroll H; Makrantonaki E; Zouboulis CC; Adjaye J BMC Genomics; 2015 Feb; 16(1):84. PubMed ID: 25765079 [TBL] [Abstract][Full Text] [Related]
6. Alzheimer's disease-related amyloid-β induces synaptotoxicity in human iPS cell-derived neurons. Nieweg K; Andreyeva A; van Stegen B; Tanriöver G; Gottmann K Cell Death Dis; 2015 Apr; 6(4):e1709. PubMed ID: 25837485 [TBL] [Abstract][Full Text] [Related]
8. Common proteomic profiles of induced pluripotent stem cell-derived three-dimensional neurons and brain tissue from Alzheimer patients. Chen M; Lee HK; Moo L; Hanlon E; Stein T; Xia W J Proteomics; 2018 Jun; 182():21-33. PubMed ID: 29709615 [TBL] [Abstract][Full Text] [Related]
9. Label-Free LC-MS/MS Proteomic Analysis of Cerebrospinal Fluid Identifies Protein/Pathway Alterations and Candidate Biomarkers for Amyotrophic Lateral Sclerosis. Collins MA; An J; Hood BL; Conrads TP; Bowser RP J Proteome Res; 2015 Nov; 14(11):4486-501. PubMed ID: 26401960 [TBL] [Abstract][Full Text] [Related]
10. Human iPSC application in Alzheimer's disease and Tau-related neurodegenerative diseases. Tcw J Neurosci Lett; 2019 Apr; 699():31-40. PubMed ID: 30685408 [TBL] [Abstract][Full Text] [Related]
11. Differential effects of acellular embryonic matrices on pluripotent stem cell expansion and neural differentiation. Yan Y; Martin LM; Bosco DB; Bundy JL; Nowakowski RS; Sang QX; Li Y Biomaterials; 2015 Dec; 73():231-42. PubMed ID: 26410789 [TBL] [Abstract][Full Text] [Related]
12. MSQ: a tool for quantification of proteomics data generated by a liquid chromatography/matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometry based targeted quantitative proteomics platform. Oh JH; Pan S; Zhang J; Gao J Rapid Commun Mass Spectrom; 2010 Feb; 24(4):403-8. PubMed ID: 20069694 [TBL] [Abstract][Full Text] [Related]
13. Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry. Oe T; Ackermann BL; Inoue K; Berna MJ; Garner CO; Gelfanova V; Dean RA; Siemers ER; Holtzman DM; Farlow MR; Blair IA Rapid Commun Mass Spectrom; 2006; 20(24):3723-35. PubMed ID: 17117458 [TBL] [Abstract][Full Text] [Related]
14. Induced pluripotent stem cells in Alzheimer's disease: applications for disease modeling and cell-replacement therapy. Yang J; Li S; He XB; Cheng C; Le W Mol Neurodegener; 2016 May; 11(1):39. PubMed ID: 27184028 [TBL] [Abstract][Full Text] [Related]
15. Targeted human cerebrospinal fluid proteomics for the validation of multiple Alzheimer's disease biomarker candidates. Choi YS; Hou S; Choe LH; Lee KH J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Jul; 930():129-35. PubMed ID: 23735279 [TBL] [Abstract][Full Text] [Related]
16. Intact protein analysis of ubiquitin in cerebrospinal fluid by multiple reaction monitoring reveals differences in Alzheimer's disease and frontotemporal lobar degeneration. Oeckl P; Steinacker P; von Arnim CA; Straub S; Nagl M; Feneberg E; Weishaupt JH; Ludolph AC; Otto M J Proteome Res; 2014 Nov; 13(11):4518-25. PubMed ID: 25091646 [TBL] [Abstract][Full Text] [Related]
17. Modeling neurodegenerative diseases with patient-derived induced pluripotent cells: Possibilities and challenges. Poon A; Zhang Y; Chandrasekaran A; Phanthong P; Schmid B; Nielsen TT; Freude KK N Biotechnol; 2017 Oct; 39(Pt B):190-198. PubMed ID: 28579476 [TBL] [Abstract][Full Text] [Related]
18. Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases. Yin GN; Lee HW; Cho JY; Suk K Brain Res; 2009 Apr; 1265():158-70. PubMed ID: 19368810 [TBL] [Abstract][Full Text] [Related]
19. Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases. Cilento EM; Jin L; Stewart T; Shi M; Sheng L; Zhang J J Neurochem; 2019 Nov; 151(4):397-416. PubMed ID: 30474862 [TBL] [Abstract][Full Text] [Related]
20. The Use of Patient-Derived Induced Pluripotent Stem Cells for Alzheimer's Disease Modeling. Lee C; Willerth SM; Nygaard HB Prog Neurobiol; 2020 Sep; 192():101804. PubMed ID: 32464173 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]